Lung Squamous Cell Carcinoma — Trials

Lung Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 37
Recruiting: 19
Ph III recruiting: 1
Growth YoY: —
Industry share: 46%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00946712	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	terminated	Phase 3	1,333	SWOG Cancer Research NetworkNETWORK	2	May 23, 2023	clinicaltrials
NCT02926638	Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches	terminated	Phase 2 / Phase 3	9	SWOG Cancer Research NetworkNETWORK